Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis

Documenti analoghi

• Erratum to: Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis
  di: Wang, Huan, et al.
  Pubblicazione: (2014)
• The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
  di: Wu, Zhen, et al.
  Pubblicazione: (2019)
• Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.
  di: Offin, Michael, et al.
  Pubblicazione: (2018)
• EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
  di: Yang, Jiyoul, et al.
  Pubblicazione: (2018)
• BRIEF REPORT: Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors
  di: Kobayashi, Susumu, et al.
  Pubblicazione: (2013)